HK1088212A1 - Designed deimmunized monoclonal antibodies for protection against hiv exposure and treatment of hiv infection - Google Patents
Designed deimmunized monoclonal antibodies for protection against hiv exposure and treatment of hiv infectionInfo
- Publication number
- HK1088212A1 HK1088212A1 HK06104458.1A HK06104458A HK1088212A1 HK 1088212 A1 HK1088212 A1 HK 1088212A1 HK 06104458 A HK06104458 A HK 06104458A HK 1088212 A1 HK1088212 A1 HK 1088212A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antibodies
- mab
- hiv
- clone
- recombinant genes
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 241001529936 Murinae Species 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108091026890 Coding region Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/342,959 US7501494B2 (en) | 2003-01-15 | 2003-01-15 | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
| PCT/US2003/035758 WO2004064724A2 (en) | 2003-01-15 | 2003-11-10 | Designed deimmunized monoclonal antibodies for protection against hiv exposure and treatment of hiv infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1088212A1 true HK1088212A1 (en) | 2006-11-03 |
Family
ID=32711841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK06104458.1A HK1088212A1 (en) | 2003-01-15 | 2006-04-12 | Designed deimmunized monoclonal antibodies for protection against hiv exposure and treatment of hiv infection |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7501494B2 (zh) |
| EP (1) | EP1583558B1 (zh) |
| CN (4) | CN101293930A (zh) |
| AT (1) | ATE501172T1 (zh) |
| AU (1) | AU2003295440B2 (zh) |
| CA (2) | CA2648056C (zh) |
| DE (1) | DE60336343D1 (zh) |
| DK (1) | DK1583558T3 (zh) |
| ES (1) | ES2362874T3 (zh) |
| HK (1) | HK1088212A1 (zh) |
| TW (2) | TWI325429B (zh) |
| WO (1) | WO2004064724A2 (zh) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1460088A1 (en) * | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
| JP5259392B2 (ja) * | 2005-05-31 | 2013-08-07 | ウォーソー・オーソペディック・インコーポレーテッド | 疼痛を治療するための組成物および方法 |
| CN102027016A (zh) * | 2008-03-13 | 2011-04-20 | 生物测试股份公司 | 一种治疗疾病的试剂 |
| RU2540018C2 (ru) * | 2008-03-13 | 2015-01-27 | Биотест Аг | Средство для лечения заболевания |
| KR20100135257A (ko) * | 2008-03-13 | 2010-12-24 | 바이오테스트 아게 | 질병 치료제 |
| US20090005320A1 (en) * | 2008-09-02 | 2009-01-01 | Bruce Kneller | Compositions comprising amino acid bicarbonate and methods of use thereof |
| CN102215867B (zh) * | 2008-09-29 | 2017-04-19 | 生物测试股份公司 | 疾病治疗用组合物 |
| AU2010242914B2 (en) | 2009-04-29 | 2014-11-13 | Trellis Bioscience, Llc | Improved antibodies immunoreactive with heregulin-coupled HER3 |
| KR101962476B1 (ko) | 2009-07-03 | 2019-03-26 | 아비펩 피티와이 리미티트 | 면역성 접합체 및 그 제조방법 |
| GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
| EP2516462B1 (en) | 2009-12-23 | 2015-05-06 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
| US20120177567A1 (en) * | 2010-08-11 | 2012-07-12 | National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government | Methods of Treating Pediatric Acute Lymphoblastic Leukemia with an Anti-CD22 Immunotoxin |
| WO2012113348A1 (zh) * | 2011-02-25 | 2012-08-30 | 厦门大学 | 抗cd4蛋白的单克隆抗体及其活性片段及用途 |
| EP2686016B1 (en) | 2011-03-14 | 2019-05-01 | Cellmid Limited | Antibody recognizing n-domain of midkine |
| EP3103810A3 (en) | 2011-04-21 | 2017-03-08 | Garvan Institute of Medical Research | Modified variable domain molecules and methods for producing and using them |
| US9193793B2 (en) | 2011-06-13 | 2015-11-24 | Csl Limited | Antibodies against G-CSFR and uses thereof |
| CN104114187A (zh) * | 2011-12-28 | 2014-10-22 | 诺沃姆德治疗公司 | 去糖基化的人类抗体、其融合蛋白质及用途 |
| CN105209057B (zh) * | 2013-03-15 | 2020-03-27 | 美国卫生和人力服务部 | 稳定的人单cd4结构域和融合蛋白 |
| BR112017005134A2 (pt) * | 2014-09-16 | 2017-12-12 | Ubi Ip Holdings | tratamento e cura funcional de infecção por hiv por anticorpos monoclonais para inibição de entrada de hiv competitiva mediada por cd |
| WO2016061632A1 (en) | 2014-10-23 | 2016-04-28 | La Trobe University | Fn14-binding proteins and uses thereof |
| US11820807B2 (en) | 2015-06-12 | 2023-11-21 | Ubi Pharma Inc | Immunoglobulin fusion proteins and uses thereof |
| CN106267406B (zh) * | 2016-07-01 | 2019-02-01 | 翁炳焕 | 艾滋病血液净化器 |
| BR112019002734A2 (pt) | 2016-08-13 | 2019-05-14 | Ubi Ip Holdings | tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart |
| EP3446710A1 (en) * | 2017-08-25 | 2019-02-27 | Glenmark Pharmaceuticals S.A. | Methods of inactivating viral contaminants |
| AU2018377856A1 (en) | 2017-11-29 | 2020-05-21 | Csl Limited | Method of treating or preventing ischemia-reperfusion injury |
| CN113683688B (zh) * | 2021-07-23 | 2023-06-23 | 无锡傲锐东源生物科技有限公司 | 抗人类免疫缺陷病毒ⅰ型p24抗原（hiv-1 p24）兔单克隆抗体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0365209A3 (en) | 1988-10-17 | 1990-07-25 | Becton, Dickinson and Company | Anti-leu 3a amino acid sequence |
| JPH06125783A (ja) | 1991-12-28 | 1994-05-10 | Chemo Sero Therapeut Res Inst | 組換え抗ｈｉｖ抗体およびその調製方法 |
| AU688880B2 (en) | 1994-03-08 | 1998-03-19 | Ludwig Institute For Cancer Research | Recombinant humanized anti-FB5 antibodies |
| US5961976A (en) * | 1996-06-03 | 1999-10-05 | United Biomedical, Inc. | Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV |
| JP3231262B2 (ja) | 1996-06-05 | 2001-11-19 | 株式会社ビー・エム・エル | ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体 |
| JPH10155489A (ja) | 1996-11-27 | 1998-06-16 | Asahi Chem Ind Co Ltd | 組換え抗体及びそれをコードする核酸 |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| CN1307640A (zh) | 1998-05-25 | 2001-08-08 | 旭化成株式会社 | 细胞分离装置和分离方法 |
-
2003
- 2003-01-15 US US10/342,959 patent/US7501494B2/en active Active
- 2003-11-10 EP EP03786626A patent/EP1583558B1/en not_active Expired - Lifetime
- 2003-11-10 WO PCT/US2003/035758 patent/WO2004064724A2/en not_active Application Discontinuation
- 2003-11-10 AT AT03786626T patent/ATE501172T1/de active
- 2003-11-10 DE DE60336343T patent/DE60336343D1/de not_active Expired - Lifetime
- 2003-11-10 DK DK03786626.6T patent/DK1583558T3/da active
- 2003-11-10 CN CNA2008100837951A patent/CN101293930A/zh active Pending
- 2003-11-10 CA CA2648056A patent/CA2648056C/en not_active Expired - Lifetime
- 2003-11-10 CA CA2512040A patent/CA2512040C/en not_active Expired - Lifetime
- 2003-11-10 ES ES03786626T patent/ES2362874T3/es not_active Expired - Lifetime
- 2003-11-10 CN CN2008100861217A patent/CN101255195B/zh not_active Expired - Lifetime
- 2003-11-10 CN CN2008100837966A patent/CN101294159B/zh not_active Expired - Lifetime
- 2003-11-10 AU AU2003295440A patent/AU2003295440B2/en not_active Ceased
- 2003-11-10 CN CNB2003801087712A patent/CN100546652C/zh not_active Expired - Lifetime
-
2004
- 2004-01-14 TW TW093100896A patent/TWI325429B/zh not_active IP Right Cessation
- 2004-01-14 TW TW097149403A patent/TWI423984B/zh not_active IP Right Cessation
-
2006
- 2006-04-12 HK HK06104458.1A patent/HK1088212A1/xx not_active IP Right Cessation
-
2008
- 2008-09-09 US US12/207,034 patent/US7872110B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN100546652C (zh) | 2009-10-07 |
| AU2003295440A1 (en) | 2004-08-13 |
| CN101294159A (zh) | 2008-10-29 |
| WO2004064724A2 (en) | 2004-08-05 |
| DK1583558T3 (da) | 2011-06-27 |
| CN101255195A (zh) | 2008-09-03 |
| DE60336343D1 (de) | 2011-04-21 |
| EP1583558B1 (en) | 2011-03-09 |
| CA2648056C (en) | 2016-01-05 |
| TWI423984B (zh) | 2014-01-21 |
| TW200418879A (en) | 2004-10-01 |
| CN1738646A (zh) | 2006-02-22 |
| US20090060914A1 (en) | 2009-03-05 |
| TWI325429B (en) | 2010-06-01 |
| CN101293930A (zh) | 2008-10-29 |
| AU2003295440B2 (en) | 2010-04-01 |
| CA2512040C (en) | 2010-06-01 |
| EP1583558A2 (en) | 2005-10-12 |
| CA2648056A1 (en) | 2004-08-05 |
| ATE501172T1 (de) | 2011-03-15 |
| CN101294159B (zh) | 2013-03-27 |
| CA2512040A1 (en) | 2004-08-05 |
| CN101255195B (zh) | 2013-05-15 |
| TW200930728A (en) | 2009-07-16 |
| US7501494B2 (en) | 2009-03-10 |
| EP1583558A4 (en) | 2007-02-28 |
| US20040137000A1 (en) | 2004-07-15 |
| WO2004064724A3 (en) | 2004-11-25 |
| US7872110B2 (en) | 2011-01-18 |
| ES2362874T3 (es) | 2011-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1088212A1 (en) | Designed deimmunized monoclonal antibodies for protection against hiv exposure and treatment of hiv infection | |
| US20210009688A1 (en) | Anti-pd-1 antibody and use thereof | |
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| WO2007103470A3 (en) | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease | |
| WO2007103469A3 (en) | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease | |
| JP2022517441A (ja) | Ｂｔｌａ抗体 | |
| JP2010521189A (ja) | 新規なヒト抗ｒ７ｖ抗体及びその使用 | |
| RU2019128192A (ru) | Антитело к epha4 | |
| Wongsaroj et al. | Modern approaches to incompatible kidney transplantation | |
| US10160802B2 (en) | Anti-malarial compositions | |
| CN112533945A (zh) | 优化的结合gp41的分子及其用途 | |
| JP2013519690A5 (zh) | ||
| CA2256306A1 (en) | Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections | |
| JP7486616B2 (ja) | Ｂｔｌａ抗体 | |
| Damelang et al. | Impact of structural modifications of IgG antibodies on effector functions | |
| Kierkels et al. | Characterization and modulation of anti-abTCR antibodies and their respective binding sites at the bTCR chain to enrich engineered T cells | |
| JP2024073580A (ja) | Ｂｔｌａ抗体 | |
| JPWO2021186056A5 (zh) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PE | Patent expired |
Effective date: 20231109 |